Education and awareness of biosimilars for healthcare professionals and consumers is essential
- GBMA supports the Australian Government’s commitment of $20million over 2015-18 for a biosimilars education and awareness initiative. However, education can only go so far in driving acceptance and uptake of biosimilars.
Uptake drivers must be introduced to support a functioning and competitive biosimilars market in Australia
- Around the world, the markets best-placed to capitalise on the benefits of biosimilars are those with a functioning competitive market, where multiple manufacturers are motivated to participate over the longer term, and where physicians are at the heart of the decision-making process.
- Successful biosimilar markets are characterised by the introduction of uptake drivers that encourage physicians to prescribe biosimilars and incentivise patients to accept biosimilars.